Risk Factors for Diagnosis of Psoriatic Arthritis, Psoriasis, Rheumatoid Arthritis, and Ankylosing Spondylitis: A Set of Parallel Case-control Studies

Elana Meer¹ , Telma Thrastardottir² , Xingmei Wang³, Maureen Dubreuil⁴ , Yong Chen³ , Joel M. Gelfand⁵ , Thorvardur J. Love² , and Alexis Ogdie⁶

ABSTRACT. *Objective.* To compare potential risk factors for the diagnosis of psoriatic arthritis (PsA), psoriasis (PsO), rheumatoid arthritis (RA), and ankylosing spondylitis (AS).

Methods. Four parallel case-control studies were conducted within The Health Improvement Network using data between 1994 and 2015. Patients with PsA, PsO, RA, or AS were identified using validated code lists and matched to controls on age, sex, practice, and year. Risk factors were selected in the time prior to diagnosis. Multivariable logistic regression models were constructed for each disease using automated stepwise regression to test potential risk factors.

Results. Patients with incident PsA (n = 7594), PsO (n = 111,375), RA (n = 28,341), and AS (n = 3253) were identified and matched to 75,930, 1,113,345, 283,226, and 32,530 controls, respectively. Median diagnosis age was 48 (IQR 38–59), 43 (IQR 28–60), 60 (IQR 48–71), and 41 (IQR 32–54) years, respectively. In multivariable models, there were some shared and some differing risk factors across all 4 diseases: PsA was associated with obesity, pharyngitis, and skin infections; PsA and PsO were associated with obesity and moderate alcohol intake; PsA and AS were associated with uveitis; and PsA and RA were associated with preceding gout. Both RA and AS were associated with current smoking, former moderate drinking, anemia, osteoporosis, and inflammatory bowel disease. All shared former or current smoking as a risk factor; statin use was inversely associated with all 4 diseases.

Conclusion. Shared and different risk factors for PsA, PsO, RA, and AS were identified. Statin use was inversely associated with all 4 conditions.

Key Indexing Terms: ankylosing spondylitis, epidemiology, psoriasis, psoriatic arthritis, rheumatoid arthritis, risk factors

Psoriasis (PsO) is a chronic inflammatory skin disease, and psoriatic arthritis (PsA), rheumatoid arthritis (RA), and axial spondyloarthritis (axSpA; which includes ankylosing spondylitis

[AS]) are chronic forms of inflammatory arthritis (IA).^{1,2,3,4} Together, these diseases affect up to 2–4% of the adult population. Each of these diseases is associated with reduced quality

This work was supported in part by the National Institutes of Health (NIH), Grant K23 AR063764, to the principal investigator AO, and internal funds from the University of Pennsylvania. MD was supported by the NIH, Grant K23 AR06912701.

¹E. Meer, BA, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; ²T. Thrastardottir, MPH, T.J. Love, MD, PhD, Department of Medicine/Rheumatology, University of Iceland and Landspítali, Reykjavik, Iceland; ³X. Wang, MD, Y. Chen, PhD, Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; ⁴M. Dubreuil, MD, Department of Medicine/Rheumatology, Boston University, Boston, Massachusetts, USA; ⁵J.M. Gelfand, MD, MSCE, Department of Biostatistics, Epidemiology and Informatics, and Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA; ⁶A. Ogdie, MD, MSCE, Department of Biostatistics, Epidemiology and Informatics, and Department of Medicine/Rheumatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

JMG has served as a consultant for BMS, Boehringer Ingelheim, Lilly, Janssen Biologics, Novartis, UCB (DSMB), Neuroderm (DSMB), Dr. Reddy's Labs, Pfizer, and Sun Pharma, receiving honoraria; receives

research grants (to the Trustees of the University of Pennsylvania) from AbbVie, Boehringer Ingelheim, Janssen, Novartis, Celgene, Ortho Dermatologics, and Pfizer; and received payment for continuing medical education work related to psoriasis that was supported indirectly by Lilly, Ortho Dermatologics, and Novartis. JMG is a co-patent holder of resiquimod for treatment of cutaneous T-cell lymphoma, is a Deputy Editor for the Journal of Investigative Dermatology, receiving honoraria from the Society for Investigative Dermatology, and is a member of the Board of Directors for the International Psoriasis Council, receiving no honoraria. TJL has received reimbursement from Celgene for speaking about guidelines for the treatment of psoriatic arthritis. AO has served as a consultant for AbbVie, Amgen, BMS, Celgene, Corrona, Global Health Living Foundation, Janssen, Lilly, Novartis, Pfizer, and Takeda, and has received grants to the University of Pennsylvania from Pfizer and Novartis and to Forward from Amgen; her husband has received royalties from Novartis. EM, TT, MD, XW, and YC declare no conflicts of interest relevant to this article.

Address correspondence to Dr. A. Ogdie, University of Pennsylvania, Division of Rheumatology, 3400 Civic Center Blvd., Philadelphia, PA 19104, USA. Email: alogdie@pennmedicine.upenn.edu.

Accepted for publication July 16, 2021.

of life, economic burden,^{5,6} and comorbidities such as cardiovascular (CV) disease.^{7,8} The early diagnosis of IA is critical to improving outcomes.⁹ In fact, many patients have joint damage within the first year of onset.¹⁰ Additionally, patients treated earlier in their disease course respond better to therapy and may have overall improved long-term outcomes.^{3,11} To achieve earlier disease identification, the development of risk scores to optimize screening methods is essential.

One way to identify patients who may be “high risk” is to identify a set of codes or diagnoses in medical records that are associated with the subsequent diagnoses of PsA, PsO, RA, and/or axSpA.¹² Once such codes are established, a sufficient number of codes/diagnoses could trigger a notification to the medical care team through the electronic medical record (EMR) itself. However, as with any screening test, a set of risk factors that would denote a high-risk patient must be both sensitive (capable of picking up the majority of patients who are likely to develop the disease) and specific (false positives are minimized so that resources are not dedicated to following individuals who do not have the disease). Given the complexity and heterogeneity of these diseases, achieving an appropriate specificity for such a test is particularly challenging.¹³ Therefore, it is crucial to better understand whether risk factors are specific to a given rheumatic disease (i.e., PsA) or more broadly applicable to patients who may develop another IA or chronic disease (i.e., PsO, RA, or axSpA). A first step in this process is to understand what factors are present prior to diagnosis that should raise a clinician’s suspicion that an inflammatory disease is present.

Rheumatic diseases, because of their systemic inflammatory component, are associated with several shared comorbidities.¹⁴ For example, PsA, PsO, RA, and axSpA have all been associated with an increased risk for CV outcomes.^{4,15,16} Additionally, these diseases may have some shared genetic factors.^{17,18,19,20} Likewise, these inflammatory conditions may have shared environmental risk factors. While individual clinical risk factors for the development of inflammatory diseases have been identified, to our knowledge no studies have compared risk factors across multiple inflammatory diseases or examined whether risk factors for PsA are similarly associated with related disorders.²¹ This study aimed to compare the strength of the association between selected potential risk factors for the development of PsA, PsO, RA, and axSpA, and to determine which risk factors are specific for PsA or shared with these other diseases.

METHODS

Study design. In this study, 4 separate case-control studies were conducted in parallel. Data from 1994 to 2015 were extracted from The Health Improvement Network (THIN), a general practitioner database in the United Kingdom.

Cases and controls. Cases were identified with at least 1 code for PsA, PsO, RA, or AS using validated code lists^{22,23,24,25} and matched to up to 10 controls from the general population without these diseases based on age (within 2.5 yrs), sex, practice, and year of diagnosis (controls were required to be in the practice on the diagnosis date and were assigned the same “diagnosis date”). Note that codes for AS are used as there are no specific codes for axSpA. Diagnosis was established based on the first of these diagnoses for

this analysis. We required at least 12 months of follow-up prior to diagnosis. Controls were excluded if they ever developed 1 of the 4 diseases.

Risk factor time period. Potential risk factors were assessed from the latest of time of enrollment into a THIN practice or the practice’s initiation of Vision software until the diagnosis date for cases or the assigned diagnosis date for controls (assigned based on the matched case’s diagnosis date). Unequal follow-up time was addressed by comparing the matched control’s first date of observation to that of the case. If the first date of observation was > 180 days before that of the case, the control’s first date of observation was shortened to fit within the 180-day window. We selected this time window as it would theoretically allow for at least 1 additional visit given that the match date was when the case had a visit.

Exposures/potential risk factors. Potential risk factors were derived from an extensive code list of over 100 covariates including common comorbidities, infections, trauma, and a more limited number of medications (e.g., statins) that were selected based on a review of the literature or a relationship to other known risk factors (e.g., obesity and hyperlipidemia in the case of statins). These code lists were derived either from validated code lists or, when no prior code list existed, agreement on the code list was established between 2 reviewers. Only hypothesized risk factors with a prevalence of $\geq 1\%$ were included in the final models and tables. Risk factors that had multiple values (e.g., BMI, smoking, alcohol) were assessed closest to the end of follow-up. The full list of potential risk factors can be found in Supplementary Table 1 (available with the online version of this article).

Statistical analysis. Univariable logistic regression was used to screen risk factors for association with the disease of interest. A multivariable logistic regression model was constructed for each disease using the significant risk factors. Automated stepwise regression was used to arrive at the final model ($P < 0.05$ to enter and $P < 0.05$ to be removed). All analyses were performed in SAS statistical software (SAS Institute). C statistics are reported with each model. Because of the large number of patients, CIs were small and statistical differences were easily identified. Thus, we denoted in tables those with a stronger association ($OR > 1.25$ or < 0.8). This cutoff was arbitrarily chosen as it is symmetric, and we felt these were more clinically meaningful risks. In a sensitivity analysis, we ran each stepwise regression model again in each sex separately to qualitatively compare models, looking for a potential effect modification by sex.

Ethical approval. This study was considered exempt by the University of Pennsylvania institutional review board (IRB; protocol #815997) and approved by the THIN Scientific Review Committee.

Patient and public involvement. Patients were not involved in this study. This study was considered exempt by the University of Pennsylvania IRB.

RESULTS

In this study, 7594 incident PsA cases, 111,375 incident PsO cases, 28,341 incident RA cases, and 3253 incident AS cases were identified and matched to 75,930, 1,113,345, 283,226, and 32,530 controls, respectively. The median age at diagnosis was 48.3 (IQR 38–59), 43.1 (IQR 28–60), 59.9 (IQR 48–71), and 40.7 (IQR 32–54) years, respectively (Table 1). Sex was balanced in PsA and PsO but more female in RA (68%) and more male in AS (70%). Mean follow-up time ranged from 6.4–7.2 years and was slightly longer among controls (Table 1). The prevalence of additional covariates tested is shown in Supplementary Table 1 (available with the online version of this article).

In univariable logistic regression models by disease, previously identified risk factors for diagnosis of the 4 diseases were replicated including obesity, uveitis, and trauma for PsA, smoking for RA, and inflammatory bowel disease (IBD) and uveitis for AS

Table 1. Baseline characteristics of the study population.

		PsA	PsA Controls	PsO	PsO Controls	RA	RA Controls	AS	AS Controls
N		7594	75,930	111,375	1,113,345	28,341	283,226	3253	32,530
Age at diagnosis, yrs	Median (IQR)	48.3 (38.1–58.6)	48.2 (38.0–58.6)	43.1 (28.3–59.7)	43.1 (28.2–59.6)	59.9 (48.0–71.1)	59.9 (48.0–71.0)	40.7 (31.7–54.3)	40.8 (31.6–54.2)
Sex	Female, n (%)	3883 (51.1)	38,830 (51.1)	58,155 (52.2)	581,356 (52.2)	19,342 (68.2)	193,342 (68.3)	979 (30.1)	9790 (30.1)
BMI	Mean (SD)	29.2 ± 6.4	27.9 ± 6.0	27.6 ± 6.3	27.3 ± 6.1	27.5 ± 6.2	27.5 ± 6.0	27.0 ± 5.6	27.6 ± 5.7
Time observed, yrs	Median (IQR)	7.2 (3.6–11.4)	7.7 (4.1–11.9)	6.7 (3.3–10.6)	7.2 (3.8–11.1)	6.4 (3.0–10.7)	6.9 (3.5–11.2)	6.4 (2.9–10.9)	6.9 (3.4–11.4)

Controls were matched on age, sex, practice, and calendar year. AS: ankylosing spondylitis; PsA: psoriatic arthritis; PsO: psoriasis; RA: rheumatoid arthritis.

(Supplementary Table 2, available with the online version of this article).

In multivariable analyses, there were some shared and some differing risk factors across all 4 diseases (Table 2). PsA was associated with a history of alcohol use (OR 1.67, 95% CI 1.45–1.93), obesity (OR 1.64, 95% CI 1.52–1.76), a previous diagnosis of gout (OR 2.19, 95% CI 1.92–2.50), pharyngitis (OR 1.23, 95% CI 1.12–1.35), skin infection (OR 1.37, 95% CI 1.28–1.46), and hand trauma (OR 1.22, 95% CI 1.03–1.44). PsO was associated with a history of smoking (OR 1.60, 95% CI 1.58–1.63), obesity (OR 1.27, 95% CI 1.25–1.30), alcohol (OR 1.27, 95% CI 1.23–1.32), prior myocardial infarction (OR 1.43, 95% CI 1.33–1.53), and trauma to bone (OR 1.29, 95% CI 1.20–1.39). RA was associated with a history of smoking (OR 1.56, 95% CI 1.51–1.61), coronary artery disease (OR 1.28, 95% CI 1.12–1.47), anemia (OR 1.26, 95% CI 1.20–1.34), a prior diagnosis of gout (OR 1.67, 95% CI 1.55–1.79), osteoporosis (OR 1.43, 95% CI 1.32–1.55), IBD (OR 1.56, 95% CI 1.37–1.78), and trauma to the joint (OR 1.25, 95% CI 1.18–1.32). Finally, AS was associated with current smoking (OR 1.31, 95% CI 1.16–1.48), former drinking (OR 1.51, 95% CI 1.21–1.88), anemia (OR 1.57, 95% CI 1.25–1.98), osteoporosis (OR 2.93, 95% CI 2.00–4.29), uveitis (OR 37.97, 95% CI 27.42–52.58), IBD (OR 5.46, 95% CI 4.12–7.23), and gastrointestinal (GI) infection (OR 1.32, 95% CI 1.05–1.66).

There were also multiple shared risk factors among certain diseases (Table 3). Both PsA and PsO diagnoses were associated with obesity and moderate alcohol intake, PsA and AS diagnoses were associated with uveitis, and PsA and RA were associated with preceding gout diagnoses and a history of former moderate alcohol intake. PsO and RA were associated with smoking (current and former) and myocardial infarction. PsO and AS were associated with current smoking. Both RA and AS were associated with current smoking, former moderate drinking, anemia, osteoporosis, and IBD. PsA, PsO, and RA shared former smoking as a risk factor, and PsO, RA, and AS shared current smoking as a risk factor. Finally, statin use was inversely associated with all 4 diseases.

When models were generated separately by sex, the findings

were generally similar although there were some differences (Supplementary Table 3, available with the online version of this article). The only factors that were significantly different were that anemia was not statistically associated with AS in women but continued to be associated with AS in men. Finally, current smoking was positively associated with PsA in women but negatively associated in men in this case-control study.

DISCUSSION

In this hypothesis-generating study, we aimed to understand similarities and differences in potential risk factors for PsA, PsO, RA, and AS and to better understand the specificity of these risk factors for the individual diseases. We conducted a broad sweep of potential risk factors that have a prevalence of at least 1% in the population, and are common enough to be useful to identify patients within an EMR setting. Overall, infections, lifestyle factors, and metabolic disease were commonly identified across the conditions, although with differential strength. Additionally, patients with PsA and RA had commonly received a diagnosis for gout or joint trauma prior to receiving a diagnosis of PsA or RA. Finally, statin use was negatively associated with the development of any one of the 4 diseases. This set of parallel case-control studies identifies some shared and some differing risk factors between these groups and is among the first studies to compare risk factors between groups.

Lifestyle factors, including smoking and alcohol consumption, were commonly identified as risk factors across different diseases though the strength of association was variable. Smoking has long been associated with RA but has a mixed association with PsA.^{17,26} Interestingly, there were sex differences in the effect of smoking on the development of PsA, with men affected less than women. Because smoking status was defined closest to diagnosis date, the differences in whether someone was an ex-smoker or current smoker may be less meaningful. Instead, these data suggest that being a smoker at any point increased the risk for inflammatory disease compared to the general population.

Metabolic risk factors, in particular obesity in PsO and PsA, and myocardial infarction in PsO and RA, were also identified. Obesity has been consistently identified as a risk factor for psoriatic disease¹³ but has not been as consistently associated with

Table 2. Multivariable logistic regression models by disease.

Risk Factor	PsA OR (95% CI)	PsO OR (95% CI)	RA OR (95% CI)	AS OR (95% CI)
Current smoker	1.01 (0.93–1.09)	1.45 (1.42–1.48)**	1.43 (1.37–1.49)**	1.31 (1.16–1.48)**
Former smoker	1.53 (1.43–1.63)**	1.60 (1.58–1.63)**	1.56 (1.51–1.61)**	1.18 (1.06–1.33)*
Current drinker	1.24 (1.08–1.42)*	1.27 (1.23–1.32)**	0.89 (0.84–0.95)*	1.14 (0.94–1.38)
Former drinker	1.67 (1.45–1.93)**	1.45 (1.39–1.50)**	1.36 (1.27–1.45)**	1.51 (1.21–1.88)*
Overweight (BMI 25–30)	1.23 (1.14–1.32)**	1.14 (1.12–1.17)**	1.01 (0.97–1.04)	
Obese (BMI > 30)	1.64 (1.52–1.76)**	1.27 (1.25–1.30)**	1.07 (1.03–1.11)*	
Hyperlipidemia		1.07 (1.04–1.10)**		
Hypertension		1.09 (1.07–1.12)**		
Diabetes	0.89 (0.80–0.98)	0.85 (0.82–0.87)**	0.86 (0.82–0.90)**	0.77 (0.64–0.94)*
MI		1.43 (1.33–1.53)**	1.20 (1.07–1.35)*	
CAD			1.28 (1.12–1.47)*	
Statin use	0.53 (0.48–0.57)**	0.60 (0.59–0.62)**	0.46 (0.44–0.47)**	0.59 (0.50–0.69)**
Anemia	1.15 (1.01–1.31)	0.77 (0.74–0.81)**	1.26 (1.20–1.34)**	1.57 (1.25–1.98)**
Acne		0.84 (0.81–0.87)**		
Anxiety		0.90 (0.87–0.92)**	0.83 (0.78–0.87)**	
Depression		0.94 (0.92–0.96)**		
Cancer	0.65 (0.60–0.71)**	0.75 (0.73–0.77)**		0.74 (0.64–0.86)**
Gout	2.19 (1.92–2.50)**	1.06 (1.01–1.12)*	1.67 (1.55–1.79)**	
Thyroid disease	1.19 (1.04–1.36)*	1.18 (1.13–1.22)**	1.39 (1.31–1.47)**	
Osteoporosis		1.12 (1.05–1.20)*	1.43 (1.32–1.55)**	2.93 (2.00–4.29)**
Uveitis	3.79 (2.77–5.18)**			37.97 (27.42–52.58)**
General eye complaints ^a	0.62 (0.56–0.68)**	0.69 (0.67–0.71)**	0.68 (0.65–0.71)**	
IBD			1.56 (1.37–1.78)**	5.46 (4.12–7.23)**
Diarrhea		0.93 (0.90–0.95)**	0.93 (0.89–0.98)*	
Infection				
GI				1.32 (1.05–1.66)*
GU		1.09 (1.05–1.14)**		
Influenza	0.56 (0.52–0.60)**	0.50 (0.49–0.51)**	0.55 (0.53–0.57)**	0.49 (0.43–0.55)**
Pharyngitis	1.23 (1.12–1.35)**	1.10 (1.08–1.13)**	1.15 (1.09–1.22)**	
Skin	1.37 (1.28–1.46)**	1.15 (1.13–1.18)**	0.96 (0.92–0.99)*	0.82 (0.71–0.94)*
Trauma				
Hand	1.22 (1.03–1.44) ^a		1.37 (1.25–1.50)**	
Joint	1.21 (1.10–1.32)**	1.03 (1.01–1.06)	1.25 (1.18–1.32)**	
Foot			1.11 (1.02–1.20)*	
Bone		1.29 (1.20–1.39)**		
Skin		1.11 (1.07–1.15)**		
Lower extremity			0.85 (0.77–0.93)*	
Nerve			0.72 (0.63–0.81)**	
Fracture	0.84 (0.75–0.93)*	0.70 (0.65–0.75)**	0.72 (0.68–0.76)**	

Empty cells indicate that the factor was not statistically significant and thus was removed from the multivariable model. Risk factors with a prevalence of > 1% in the control population are included. Highlighted in yellow are risk factors with an effect size > 1.25 and a significant association with $P < 0.01$. Highlighted in blue are risk factors with an effect size of < 0.8 and a significant association with $P < 0.01$. ^a General eye complaints were a broad category that included vision loss, blurry vision, retinal artery occlusion, and referral to ophthalmology. * P value < 0.02. ** P value < 0.001. AS: ankylosing spondylitis; CAD: coronary artery disease; GI: gastrointestinal; GU: genitourinary; IBD: inflammatory bowel disease; MI: myocardial infarction; PsA: psoriatic arthritis; PsO: psoriasis; RA: rheumatoid arthritis.

RA.¹⁷ Additionally, CV morbidity and mortality are known to be associated with these systemic inflammatory conditions.^{7,8,15} These results suggest these associations exist prior to diagnosis and may further suggest that the inflammatory disease is ongoing well before diagnosis.²⁷ In addition, the results also suggest negative associations between diabetes and the rheumatic diseases, which is surprising given the comorbidity and autoimmune associations. This relationship may be because of a protective effect of diabetes medications (metformin or thiazolidinediones) directly through decreased inflammation or indirectly through

the improvement of lifestyle factors.^{28,29,30} Because many of the cardiometabolic diseases travel together, there was the potential for collinearity. We explored the insertion and removal of individual risk factors using an alternative modeling approach (purposeful selection) and there was minimal effect on the final models (sensitivity analysis not shown).

Another intriguing finding in this study was the association between statin use and a decreased likelihood of having inflammatory disease. Previous studies have found a decreased risk for the development of RA in statin users.^{17,31} Our findings

Table 3. Summary of unique and shared risk factors positively associated with diagnosis of PsA, PsO, RA, and AS.

	PsA	PsO	RA	AS
PsA	Overweight, pharyngitis, skin infections	Former smoking, obesity, alcohol	–	–
PsO	Obesity, alcohol, former smoking	MI, bone trauma	–	–
RA	Gout, joint trauma, hand trauma	Smoking (current and former), MI/CAD	Thyroid disease	–
AS	Uveitis	Current smoking	Current smoking, former drinking, anemia, osteoporosis, IBD	GI infection

AS: ankylosing spondylitis; CAD: coronary artery disease; GI: gastrointestinal; IBD: inflammatory bowel disease; MI: myocardial infarction; PsA: psoriatic arthritis; PsO: psoriasis; RA: rheumatoid arthritis.

suggest that this decreased risk is not unique to RA but rather extends to other inflammatory conditions. However, further studies are needed to better understand this relationship. It may be that patients who receive statins are different in other ways. For example, they may be receiving better preventive care or may have differences in lifestyle factors.

Infections have long been suspected to be associated with the development of autoimmune disease,³² and patients often cite infections as triggers for their disease. In our study, we found that pharyngitis and skin infections were significantly associated with the development of PsA, and GI infections were associated with the development of AS. These findings are intriguing as prior studies have linked streptococcus and/or staphylococcus infections with the development of PsO.³³ Additionally, GI infections (in particular shigella, salmonella, and campylobacter) have previously been linked to the development of reactive arthritis.³⁴ Eder et al previously identified “infections requiring antibiotics” as a risk factor associated with the development of PsA.³⁵ Thus, these results not only support previous theories of pathophysiologic triggers related to these diseases but also demonstrate some commonalities between diseases. Finally, interestingly, influenza was negatively associated with the development of IA. The rationale for this association is not clear. To our knowledge, only 1 study has addressed influenza and the risk for RA. In this ecological study, there was no apparent association.³⁶ It may be that patients who had influenza had better primary care follow-up or other competing risks, or patients who were observed more closely received the influenza vaccine and were also more likely to have diagnoses such as one of these inflammatory diseases. Cohort studies are needed to better study the association between these infections and the development of IA or PsO.

The results of this study should be considered in light of some limitations. First, the use of an EMR, while practical, relies on codes placed by healthcare professionals, meaning codes for certain diagnoses (or risk factors) may be missing, and thus there may be misclassification of both the exposures and outcomes.³⁷ This may have affected the results of the study. We assume this to be nondifferential misclassification, meaning that the estimates would be biased toward the null³⁷ and the misclassification

would not lead to excessive type I error.³⁸ However, this is also the “real world” and mimics the way similar algorithms would be built within the EMR to identify patients at increased risk for development of these inflammatory conditions. Further, missed diagnoses of IA have been demonstrated to be common, at least among patients with PsA and likely the other groups as well, potentially influencing the results of this study.³⁹ In addition, the definition of incident diagnosis required 1 year of time in the practice prior to diagnosis. It is possible, however, that patients may have had the disease ongoing for a period of time prior to diagnosis. The case-control design is a limitation in that these inflammatory diseases may have been ongoing for many years prior to diagnosis, and thus risk factors may represent disease features or signs of disease rather than being causal. In fact, many patients who later were diagnosed with RA or PsA were first given diagnoses of trauma or gout, suggesting the disease was ongoing well before the diagnosis was finally made but not yet labeled correctly. Similarly, AS diagnoses were associated with uveitis and IBD, which are known comorbidities of AS. However, the associations are still valuable in identifying the earliest features of a syndrome and have clinical utility in prompting suspicion for other manifestations.

Despite these limitations, this study also has strengths. This study was a first step toward identifying potential risk factors for all 4 diseases using a wide-based approach to identify all possible associations. Further, the value of this study is strengthened by the use of a large cohort of patients, the previous validation of codes, the use of a primary care EMR dataset, and the replication of previous risk factors, all of which support the external validity of these results. Finally, there are relatively few studies that have addressed risk factors for AS.¹⁶

In summary, the goal of this study was to identify potential predictors that could be used within an EMR to detect patients who may be at higher risk of developing these inflammatory conditions. We performed a set of parallel case-control studies to address this question and identified potential risk factors across inflammatory diseases and some that were different between diseases. Inclusion of all 4 diseases was important in order to consider whether such algorithms should be designed to identify patients across these conditions or whether individual

algorithms for each disease type should be tested. This was a hypothesis-generating study; the goal was not to identify causal or etiologic associations (the case-control design also limits this ability). Future cohort studies are needed to further explore the causal effects of the identified predictors. Additionally, these future studies will examine the positive predictive value of combinations of these risk factors in identifying patients with early inflammatory disease. Such combinations of risk factors can then be used in trials to enroll high-risk patients in intervention studies aiming to prevent disease.^{40,41}

ONLINE SUPPLEMENT

Supplementary material accompanies the online version of this article.

ACKNOWLEDGMENT

We thank Tori Fischer for administrative and editorial support.

REFERENCES

- Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. *Lancet* 2016;388:2023-38.
- Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. *N Engl J Med* 2017;376:2095-6.
- Sieper J, Poddubnyy D. Axial spondyloarthritis. *Lancet* 2017;390:73-84.
- Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. *J Am Acad Dermatol* 2017;76:377-90.
- Mars NJ, Kerola AM, Kauppi MJ, Pirinen M, Elonheimo O, Sokka-Isler T. Patients with rheumatic diseases share similar patterns of healthcare resource utilization. *Scand J Rheumatol* 2019;48:300-7.
- Kimball AB, Guérin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. *J Eur Acad Dermatol Venereol* 2011;25:157-63.
- Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. *Ann Rheum Dis* 2015;74:326-32.
- Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. *JAMA* 2006;296:1735-41.
- Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. *Nat Rev Dis Primers* 2018;4:18001.
- Kane D, Stafford L, Bresnihan B, FitzGerald O. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. *Rheumatology* 2003;42:1460-8.
- Kirkham B, de Vlam K, Li W, et al. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. *Clin Exp Rheumatol* 2015;33:11-9.
- Jensen PB, Jensen LJ, Brunak S. Mining electronic health records: towards better research applications and clinical care. *Nat Rev Genet* 2012;13:395-405.
- Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. *Nat Rev Rheumatol* 2019;15:153-66.
- Gottlieb AB, Dann F. Comorbidities in patients with psoriasis. *Am J Med* 2009;122:1150.e1-9.
- Ferguson LD, Siebert S, McInnes IB, Sattar N. Cardiometabolic comorbidities in RA and PsA: lessons learned and future directions. *Nat Rev Rheumatol* 2019;15:461-74.
- Wang R, Ward MM. Epidemiology of axial spondyloarthritis: an update. *Curr Opin Rheumatol* 2018;30:137-43.
- Deane KD, Demoruelle MK, Kelmenson LB, Kuhn KA, Norris JM, Holers VM. Genetic and environmental risk factors for rheumatoid arthritis. *Best Pract Res Clin Rheumatol* 2017;31:3-18.
- Hammaker D, Firestein GS. Epigenetics of inflammatory arthritis. *Curr Opin Rheumatol* 2018;30:188-196.
- Brown MA, Wordsworth BP. Genetics in ankylosing spondylitis – current state of the art and translation into clinical outcomes. *Best Pract Res Clin Rheumatol* 2017;31:763-76.
- Boehncke WH, Schön MP. Psoriasis. *Lancet* 2015;386:983-94.
- Scherer HU, Häupl T, Burmester GR. The etiology of rheumatoid arthritis. *J Autoimmun* 2020:102400.
- Seminara NM, Abuabara K, Shin DB, et al. Validity of The Health Improvement Network (THIN) for the study of psoriasis. *Br J Dermatol* 2011;164:602-9.
- Ogdie A, Alehashemi S, Love TJ, et al. Validity of psoriatic arthritis and capture of disease modifying antirheumatic drugs in the health improvement network. *Pharmacoepidemiol Drug Saf* 2014; 23:918-22.
- Rodríguez LA, Tolosa LB, Ruigómez A, Johansson S, Wallander MA. Rheumatoid arthritis in UK primary care: incidence and prior morbidity. *Scand J Rheumatol* 2009;38:173-7.
- Dubreuil M, Peloquin C, Zhang Y, Choi HK, Inman RD, Neogi T. Validity of ankylosing spondylitis diagnoses in The Health Improvement Network. *Pharmacoepidemiol Drug Saf* 2016; 25:399-404.
- Nguyen US, Zhang Y, Lu N, et al. Smoking paradox in the development of psoriatic arthritis among patients with psoriasis: a population-based study. *Ann Rheum Dis* 2018;77:119-23.
- Ogdie A. The preclinical phase of PsA: a challenge for the epidemiologist. *Ann Rheum Dis* 2017;76:1481-3.
- Glossmann H, Reider N. A marriage of two “Methusalem” drugs for the treatment of psoriasis?: arguments for a pilot trial with metformin as add-on for methotrexate. *Dermatoendocrinol* 2013;5:252-63.
- Singh S, Bhansali A. Randomized placebo control study of insulin sensitizers (metformin and pioglitazone) in psoriasis patients with metabolic syndrome (Topical Treatment Cohort). *BMC Dermatol* 2016;16:12.
- Seong JM, Yee J, Gwak HS. Dipeptidyl peptidase-4 inhibitors lower the risk of autoimmune disease in patients with type 2 diabetes mellitus: a nationwide population-based cohort study. *Br J Clin Pharmacol* 2019;85:1719-27.
- Myasoedova E, Karmacharya P, Duarte-Garcia A, Davis JM III, Murad MH, Crowson CS. Effect of statin use on the risk of rheumatoid arthritis: a systematic review and meta-analysis. *Semin Arthritis Rheum* 2020;50:1348-56.
- Kudaeva FM, Speechley MR, Pope JE. A systematic review of viral exposures as a risk for rheumatoid arthritis. *Semin Arthritis Rheum* 2019;48:587-96.
- Fry L, Baker BS. Triggering psoriasis: the role of infections and medications. *Clin Dermatol* 2007;25:606-15.
- Ajene AN, Fischer Walker CL, Black RE. Enteric pathogens and reactive arthritis: a systematic review of *Campylobacter*, *salmonella* and *Shigella*-associated reactive arthritis. *J Health Popul Nutr* 2013;31:299-307.
- Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: a prospective cohort study. *Arthritis Rheumatol* 2016;68:915-23.
- Kudaeva F, Speechley M, Klar N, et al. Association of arthritis onset with influenza: analysis of the Canadian Early Inflammatory Arthritis Cohort. *ACR Open Rheumatol* 2019;1:63-9.
- Neuhaus J. Bias and efficiency loss due to misclassified responses in binary regression. *Biometrika* 1999;86:843-55.

38. Duan R, Cao M, Wu Y, et al. An empirical study for impacts of measurement errors on EHR based association studies. *AMIA Annu Symp Proc* 2017;2016:1764-73.
39. Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. *J Am Acad Dermatol* 2013;69:729-35.
40. Bell S, Merola JF, Webster DE, et al. Aiming for cure and preventive initiatives in psoriatic disease: building synergy at NPF, GRAPPA, and PPACMAN. *Curr Rheumatol Rep* 2020;22:78.
41. Perez-Chada LM, Haberman RH, Chandran V, et al. Consensus terminology for preclinical phases of psoriatic arthritis for use in research studies: results from a Delphi consensus study. *Nat Rev Rheumatol* 2021;17:238-43.